The Science Behind
Safer Period Care

Broad survey of chemicals present across product types, phthalates, parabens, phenols. Highlights potential for endocrine exposure and a need for transparency in menstrual product composition.

Found toluene in most pads, microplastic shedding and in-vitro cytotoxicity signals. Demonstrates that commercial pads release harmful substances during normal use.

Synthesis of evidence on VOCs, phthalates, metals and other constituents in pads/tampons. Identifies data gaps and calls for standardized testing and disclosure.

Measured metals (e.g., lead, cadmium, others) in tampons and estimated exposures. Underscores need for stricter quality control across menstrual products.

Reported comparatively high phthalate levels in pads/diapers, raising concern about intimate exposure routes. Products designed for intimate contact had higher chemical loads than everyday plastics.

Identified multiple volatile organic compounds and performed exposure/risk assessment for pad users. Quantifies the level of chemical exposure during normal pad usage.

Reviews hazard identification and exposure assessments for pad constituents. Outlines conservative models used by regulators and industry, revealing gaps in current safety standards.

Across 22 human studies, most showed higher BPA exposure among women with PCOS/PMOS. Establishes a clear epidemiological association between BPA exposure and polycystic ovary syndrome.

Summarizes human data suggesting associations between prenatal or higher phthalate exposure and PCOS/PMOS features. Emphasizes the need for better-designed longitudinal studies.

Adolescent BPA exposure induced PCOS/PMOS-like syndrome and fertility effects in rats. Supports biological plausibility of endocrine-disrupting chemical mechanisms, not just correlational but causal.

Metabolomics analysis suggests disrupted steroid and lipid pathways in BPA-exposed PCOS/PMOS patients. Reveals the molecular mechanisms through which endocrine disruptors affect hormonal health.